Tennessee Valley Asset Management Partners Nektar Therapeutics Transaction History

Tennessee Valley Asset Management Partners

$594 Million
Q4 2024

1 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2023 Jan 29, 2024	BUY	$0.42 - $0.57 $0 - $0	0 New	0 $0

Others Institutions Holding NKTR

# of Institutions

153

Shares Held

131M

Call Options Held

92.7K

Put Options Held

4.9K

Black Rock Inc. New York, NY

15.2M
Shares

$13 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

12.3M
Shares

$10.6 Million
0.0% of portfolio
Samlyn Capital, LLC New York, NY

9.67M
Shares

$8.31 Million
0.14% of portfolio
Nantahala Capital Management, LLC New Canaan, CT

7.81M
Shares

$6.72 Million
0.37% of portfolio
Acadian Asset Management LLC Boston, MA

7.2M
Shares

$6.19 Million
0.02% of portfolio

View Full List

About NEKTAR THERAPEUTICS

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $161M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

More about NKTR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tennessee Valley Asset Management Partners, based on Form 13F filings with the SEC.

News

Stay updated on Tennessee Valley Asset Management Partners with notifications on news.

Account